Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Multiple dosing strategies with acetyl L-carnitine (ALCAR) fail to alter age-related hearing loss in the Fischer 344/NHsd rat | Journal of Negative Results in BioMedicine BioMed Central Research Open Access Multiple dosing strategies with acetyl L-carnitine ALCAR fail to alter age-related hearing loss in the Fischer 344 NHsd rat Eric C Bielefeld Donald Coling Guang-Di Chen and Donald Henderson Address Center for Hearing and Deafness Department of Communicative Disorders and Sciences State University of New York at Buffalo 137 Cary Hall 3435 Main Street Buffalo NY 14214 USA Email Eric C Bielefeld - ecb2@ Donald Coling - dcoling@ Guang-Di Chen - gchen7@ Donald Henderson - donaldhe@ Corresponding author Published II July 2008 Received II March 2008 Journal of Negative Results in BioMedicine 2008 7 4 doi 1477-5751-7-4 Accepted 11 July 2008 This article is available from http content 7 1 4 2008 Bielefeld et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background The Fischer 344 NHsd rat undergoes age-related progressive high-frequency hearing loss beginning at age 12 months. The loss has been linked to defects death in the outer hair cells related to oxidative stress originating in the mitochondria. Acetyl L-carnitine ALCAR is known to enhance mitochondrial bioenergetics and membrane efficiency. Therefore ALCAR was targeted as a possible pharmacologic intervention to prevent or even restore hearing loss from aging. Methods Three different paradigms were used to deliver ALCAR to aging Fischer 344 NHsd rats. Rats in each condition had their hearing evaluated by auditory brainstem responses before during and after treatment. First 24-month-old rats were given ALCAR 100 mg kg dissolved 25 mg ml in saline by IP injection daily for one month. Second 18-month-old rats were given .
